Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pearl Street Venture Funds (PSVF) is a venture capital firm co-founded in 2003 by John H. Barnard, Michael Brennan, Stella M. Sung, and Tim Tichenor. Based in Indianapolis, Indiana, the firm employs an operator-led approach to value creation, focusing on early-stage life sciences companies. PSVF has a notable history of investing in innovative firms within the biotech and healthcare sectors, aiming to transform these industries through scientific and technological advancements.
As of now, Pearl Street Venture Funds is recognized as a legacy investor, having fully invested its capital and not actively seeking new investments. The firm has participated in significant funding rounds and acquisitions, including the notable exit of Grand River Aseptic Manufacturing, acquired by Arlington Capital Partners in November 2017. The firm’s cumulative experience includes investments in 37 life sciences companies, with founders or lead investors in 25 of those.
Pearl Street Venture Funds specializes in early-stage investments within the life sciences sector, particularly focusing on biotechnology, pharma services, and healthcare innovation. The firm seeks to invest in companies that demonstrate science and technology-driven differentiation, aligning with their thesis of fostering advancements in drug discovery technology and cancer signaling research. Their investment strategy emphasizes a hands-on approach, leveraging the extensive experience of their team in the life sciences industry.
PSVF typically engages in Seed, Series A, and Series B funding rounds, primarily targeting North American companies. The firm values founders who possess a strong vision and a commitment to innovation in the life sciences field. While specific check sizes and fund metrics are not publicly disclosed, the firm’s historical investments indicate a preference for substantial early-stage funding to support growth and development.
Pearl Street Venture Funds has a notable portfolio that includes several key players in the life sciences sector. Among these, CoLucid Pharmaceuticals stands out, having raised $37.1 million in a Series C funding round with participation from various prominent investors. This investment highlights PSVF's commitment to supporting innovative companies in the biotech space.
Another significant achievement for the firm is the acquisition of Grand River Aseptic Manufacturing, which was acquired by Arlington Capital Partners in November 2017. This exit underscores the firm's ability to identify and nurture companies that can achieve substantial market success. Overall, PSVF's portfolio reflects a strong focus on companies that are at the forefront of life sciences innovation.
John H. Barnard, MBA - Co-founder of Pearl Street Venture Funds, Barnard brings extensive experience in the life sciences sector and venture capital. His background includes leadership roles in various biotech firms.
Michael Brennan, MD - Co-founder and medical doctor, Brennan has a strong background in healthcare and life sciences, contributing valuable insights into the medical aspects of potential investments.
Stella M. Sung, PhD - Co-founder with a PhD in a relevant field, Sung's expertise lies in scientific research and innovation, making her a key asset in evaluating biotech opportunities.
Tim Tichenor, MBA - Co-founder and experienced venture capitalist, Tichenor has a diverse background in finance and investment, enhancing the firm's strategic decision-making capabilities.
As of now, Pearl Street Venture Funds is recognized as a fully invested fund, with no new investments reported since the early 2010s. The most recent notable event was the acquisition of Grand River Aseptic Manufacturing by Arlington Capital Partners in November 2017. This acquisition marked a significant exit for the firm, showcasing its ability to identify and support successful life sciences companies.
Due to the firm's current status as a legacy investor, there have been no recent announcements or activities indicating new funding rounds or investments.
What are Pearl Street Venture Funds' investment criteria?
PSVF focuses on early-stage life sciences companies, particularly in biotech, pharma services, and healthcare innovation. They look for companies that demonstrate science and technology-driven differentiation.
How can I pitch to Pearl Street Venture Funds?
While specific application processes are not detailed, it is advisable to prepare a comprehensive pitch deck that outlines your business model, market potential, and technological innovations. Engaging with the firm through industry connections may enhance your chances of securing a meeting.
What makes Pearl Street Venture Funds different from other investors?
PSVF employs an operator-led approach, meaning they leverage their extensive experience in the life sciences industry to provide hands-on support to portfolio companies. This approach distinguishes them from many traditional venture capital firms.
What is the geographic focus of Pearl Street Venture Funds?
The firm primarily invests in North American companies, concentrating on those within the life sciences sector.
What is the typical check size for investments?
Specific check sizes are not publicly disclosed, but the firm is known to participate in substantial funding rounds for early-stage companies, indicating a willingness to invest significant capital to support growth.
What is the current status of Pearl Street Venture Funds?
As of now, PSVF is considered a legacy investor, having fully invested its capital and not actively seeking new investments. Their last notable acquisition occurred in November 2017.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.